Literature DB >> 305674

Thymosin treatment of children with primary immunodeficiency disease.

D W Wara, A J Ammann.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1978        PMID： 305674

Source DB:  PubMed          Journal:  Transplant Proc        ISSN： 0041-1345            Impact factor:   1.066


× No keyword cloud information.
  8 in total

1.  Immunomodulation and therapeutic characterization of thymosin fraction five.

Authors:  J E Talmadge; K A Uithoven; B F Lenz; M Chirigos
Journal:  Cancer Immunol Immunother       Date:  1984       Impact factor: 6.968

2.  Influenza and aging: age-related changes and the effects of thymosin on the antibody response to influenza vaccine.

Authors:  W B Ershler; A L Moore; M A Socinski
Journal:  J Clin Immunol       Date:  1984-11       Impact factor: 8.317

Review 3.  Combined immunodeficiency and thymic abnormalities.

Authors:  A D Webster
Journal:  J Clin Pathol Suppl (R Coll Pathol)       Date:  1979

Review 4.  Chronic mucocutaneous candidiasis.

Authors:  C H Kirkpatrick
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1989-05       Impact factor: 3.267

5.  Intestinal lymphangiectasia and thymic hypoplasia.

Authors:  R U Sorensen; T C Halpin; C R Abramowsky; D L Hornick; K M Miller; P Naylor; G S Incefy
Journal:  Clin Exp Immunol       Date:  1985-01       Impact factor: 4.330

6.  Dual action of leucocyte dialysates and of thymosin on the recovery of sheep-cell-rosetting capacity in trypsinized human lymphocytes.

Authors:  I L Sargent; M R Salaman; H Valdimarsson
Journal:  Clin Exp Immunol       Date:  1982-01       Impact factor: 4.330

7.  Experimental autoimmune thyroiditis: modulation of the disease level in high and low responder mice by thymosin.

Authors:  V Tomazic; C M Suter; P B Chretien
Journal:  Clin Exp Immunol       Date:  1984-10       Impact factor: 4.330

8.  Improvement of natural killer activity and of T cells after thymopoietin pentapeptide therapy in a patient with severe combined immunodeficiency.

Authors:  M Fiorilli; M C Sirianni; F Pandolfi; I Quinti; U Tosti; F Aiuti; G Goldstein
Journal:  Clin Exp Immunol       Date:  1981-08       Impact factor: 4.330
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.